Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors

Core Points - OSE Immunotherapeutics held its Annual General Meeting, where shareholders representing approximately 56% of the share capital and over 62% of voting rights participated in key decisions for the company's future [1] - Dr. Markus Cappel was elected as the new Chairman of the Board of Directors, expressing enthusiasm for advancing the company's promising pipeline and novel medicines [3] - The company has a strong pipeline of innovative drug candidates and has achieved positive clinical trial results, positioning it as a significant player in the immunotherapy landscape [4] Board of Directors - The shareholders voted in favor of appointing new directors, including Dr. Markus Cappel and Alexis Peyroles [2] - The new Board of Directors held its first meeting post-election and confirmed its confidence in the employees' commitment to developing novel medicines [5] Dr. Markus Cappel's Background - Dr. Markus Cappel has over thirty years of experience in the biotechnology sector and is recognized for his entrepreneurial spirit and achievements [6] - As Chief Business Officer of ChemoCentryx, he led product development and negotiations that secured commercial rights and development control in the U.S. [7] - He played a key role in ChemoCentryx's acquisition by Amgen for $4 billion, which represented a 116% premium [8] Company Overview - OSE Immunotherapeutics is dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation, addressing unmet patient needs [11] - The company collaborates with leading academic institutions and biopharmaceutical companies to bring transformative medicines to market [11]